Synthesis, crystal structure, and antinociceptive effects of some new riluzole derivatives
Tóm tắt
Nine N-alkylated derivatives of riluzole were synthesized in order to obtain new compounds with potential antinociceptive activity. Riluzole was firstly transformed into (6-trifluoromethoxy-benzothiazol-2-yl)-hydrazine, then it was chlorinated by SOCl2 to obtain 2-chloro-6-trifluoromethoxy-benzothiazole. This intermediate product was treated with nine alkylamines to give N-alkylated derivatives of riluzole respectively. The structures of compounds were confirmed by means of elemental analysis, IR, 1H NMR, and 13C NMR. The synthetic route was optimized and four novel crystals were obtained by recrystallization. This study investigated the antinociceptive activity of some N-alkylated derivatives of riluzole by hot plate test in mice. The relationship between antinociceptive activity and the doses of 4b, 4c, 4h, 4g, and riluzole had been studied. Compared with the control group (0 mg/kg), the effects of compounds 4b and 4h showed a significant increase (13.78 ± 2.89 s, 12.89 ± 2.94 s, respectively). Compound 4c showed extreme significant increase (18.07 ± 3.08 s) in the time mice spent on the hot plate. The compounds 4b, 4c, and 4h had increased the latency time compared to the blank solvent group. They have potential application in developing new drug candidates with antinociceptive activity.
Tài liệu tham khảo
Cheah BC, Vucic S, Krishnan AV, Kiernan MC (2010) Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 17:1942–1959
Cheung YK, Gordon PH, Levin B (2006) Selective promising ALS therapies in clinical trials. Neurology 67:1748–1751
Chew DJ, Carlstedt T, Shortland PJ (2014) The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. J Pain 5:664–675
Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN (2015) The riluzole derivative 2-amino-6-trifluoromethylthiobenzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics 12:234–249
Domino EF, Unna KR, Kerwin J (1952) Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action. J Pharmacol Exp Ther 105:486–497
Gegelashvili G, Bjerrum OJ (2014) High-affinity glutamate transporters in chronic pain: an emerging therapeutic target. J Neurochem 131:712–730
Jehle T, Bauer J, Blauth E, Hummel A, Darstein M, Freiman TM, Feuerstein TJ (2000) Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 130:1227–1234
Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y, Mignani S (1999) Riluzole series. Synthesis and in vivo “antiglutamate” activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino- benzothiazolines. J Med Chem 42:2828–2843
Joyce LL, Batey RA (2009) Heterocycle formation via palladium-catalyzed intramolecular oxidative C−H bond functionalization: an efficient strategy for the synthesis of 2-aminobenzothiazoles. Org Lett 11:2792–2795
Kaplancikli ZA, Altintop MD, Turan-Zitouni G, Ozdemir A, Can OD (2012) Synthesis and analgesic activity of some acetamide derivatives. J Enzym Inhib Med Chem 27:275–280
Liu AY, Mathur R, Mei N, Langhammer CG, Babiarz B, Firestein BL (2011) Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem 286:2785–2794
Mignani S, Audiau F, Blevec JL (1992) Versatile methods for the synthesis of 2-amino-6-trifluoromethoxy-(nitro) benzothiazoles. Synth Commun 22:2769–2780
Mishra SP, Shukla SK, Pandey BL (2014) A preliminary evaluation of comparative effectiveness of riluzole in therapeutic regimen for irritable bowel syndrome. Asian Pac J Trop Biomed 4:S335–340
Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—I: Anticonvulsant properties. Neuropharmacol 24:767–773
Moon ES, Karadimas SK, Yu WR, Austin JW, Fehlings MG (2014) Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. Neurobiol Dis 62:394–406
Nicholson KJ, Zhang S, Gilliland TM, Winkelstein BA (2014) Riluzole effects on behavioral sensitivity and the development of axonal damage and spinal modifications that occur after painful nerve root compression. J Neurosurg Spine 20:751–762
Queiroz RB, Carvalho FL, Fonsêca DV, Barbosa-Filho JM, Salgado PR, Paulo LL, Queiroz AB, Pordeus LC (2015) Antinociceptive effect of hydantoin 3-phenyl-5-(4 -ethylphenyl)- imidazolidine-2, 4-dione in mice. Molecules 20:974–986
Rana A, Siddiqui N, Kahn SA (2007) Benzothiazoles: a new profile of biological activities. Indian J Pharm Sci 69:10–17
Saha P, Ramana T, Purkait N, Ali MA, Paul R (2009) Ligand-free copper-catalyzed synthesis of substituted benzimidazoles, 2-aminobenzimidazoles, 2-aminobenzothiazoles, and benzoxazoles. J Org Chem 74:8719–8725
Sommer B, Seeburg PH (1992) Glutamate receptor channels: novel properties and new clones. Trends Pharmacol Sci 13:291–296
Turan-Zitouni G, Yurttaş L, Kaplancikli ZA, Can OD (2015) Synthesis and anti-nociceptive, anti-inflammatory activities of new aroyl propionic acid derivatives including N-acylhydrazone motif. Med Chem Res 24:2406–2416
Wilson JR, Fehlings MG (2013) Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy. World Neurosurg 81:825–829